Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population
| Autor: | Dulce Dajheanne García-de la Cruz, Nancy Adanelly López-Martínez, Francisco Caballero-Prado, José Jaime Martínez-Magaña, Crystell Guadalupe Guzmán-Priego, Alma Delia Genis-Mendoza, Isela Esther Juárez-Rojop, Thelma Beatriz González-Castro, Javier Antonio Hernández-Cisneros, Humberto Nicolini, Carlos Alfonso Tovilla-Zárate |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
business.industry
Montreal Cognitive Assessment Cognition Disease medicine.disease Mental health 030227 psychiatry 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Schizophrenia medicine Biomarker (medicine) Effects of sleep deprivation on cognitive performance business 030217 neurology & neurosurgery Clinical psychology |
| Zdroj: | Neuropsychiatric Disease and Treatment. 15:1717-1722 |
| ISSN: | 1178-2021 |
| DOI: | 10.2147/ndt.s208587 |
| Popis: | Background Circulating cell-free mitochondrial DNA (cf-mtDNA) fragments in blood plasma have been reported in patients with schizophrenia (SZ). Although the relationship of cf-mtDNA to the cognitive status of patients with SZ has not yet been explored, it is known that cognitive impairment in SZ compromises the functional and social capacity of these patients and diminishes their quality of life. In this sense, the assessment of the severity of cognitive impairment in a Mexican population with SZ and its association with cf-mtDNA levels in blood plasma may provide the possibility of using cf-mtDNA as a biomarker to determine the status of the disease and the possible ensuing changes over time. Methods Subjects for a case-control study will be recruited. cf-mtDNA obtained from blood plasma will be quantified by real-time polymerase chain reaction, using melting curve technology with SYBR green as amplification marker. Patients with SZ will be grouped into those with severe, mild, and no cognitive impairment according to Montreal Cognitive Assessment scale scores, to determine differences between cognitive performance and cf-mtDNA levels in blood plasma. Ethics and communication This study has been approved by the ethics and investigation committees of the High Specialty Regional Hospital of Mental Health (Hospital Regional de Alta Especialidad de Salud Mental); project No. HRAESM/DG/RP/1128/2018. We plan to communicate our research findings in scientific conferences and in peer-reviewed journals. Conclusion It is known that cognitive dysfunction provokes negative effects in an SZ patient´s life. This project aims to provide better knowledge about the role of cf-mtDNA in the pathogenesis of cognitive impairment in SZ, as an attempt to achieve improvements to the existing treatments, thereby helping to prevent major cognitive deterioration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|